BRPI0814644A2 - Anticorpos para cd200 e usos destes na inibição de respostas imunes. - Google Patents

Anticorpos para cd200 e usos destes na inibição de respostas imunes.

Info

Publication number
BRPI0814644A2
BRPI0814644A2 BRPI0814644-6A2A BRPI0814644A BRPI0814644A2 BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2 BR PI0814644 A BRPI0814644 A BR PI0814644A BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2
Authority
BR
Brazil
Prior art keywords
antibodies
inhibiting immune
answers
immune answers
inhibiting
Prior art date
Application number
BRPI0814644-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Russell P Rother
Susan Faas Micknight
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BRPI0814644A2 publication Critical patent/BRPI0814644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814644-6A2A 2007-07-25 2008-07-25 Anticorpos para cd200 e usos destes na inibição de respostas imunes. BRPI0814644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
PCT/US2008/009037 WO2009014745A1 (fr) 2007-07-25 2008-07-25 Anticorps dirigés contre cd200 et leurs utilisations dans l'inhibition de réponses immunitaires

Publications (1)

Publication Number Publication Date
BRPI0814644A2 true BRPI0814644A2 (pt) 2015-01-27

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814644-6A2A BRPI0814644A2 (pt) 2007-07-25 2008-07-25 Anticorpos para cd200 e usos destes na inibição de respostas imunes.

Country Status (9)

Country Link
US (3) USRE46323E1 (fr)
EP (1) EP2178561A1 (fr)
JP (4) JP2010534243A (fr)
KR (1) KR20100041849A (fr)
AU (1) AU2008279619B2 (fr)
BR (1) BRPI0814644A2 (fr)
CA (1) CA2697159C (fr)
MX (1) MX2010000981A (fr)
WO (1) WO2009014745A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用
MX2012009321A (es) 2010-02-11 2012-11-21 Alexion Pharma Inc Metodos terapeuticos que utilizan anticuerpos anti-cd200.
WO2012106634A1 (fr) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Utilisation d'un anticorps anti-cd200 pour prolonger la survie d'allogreffes
CA2837357C (fr) 2011-06-10 2020-07-07 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anticorps antiricine et leurs utilisations
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
WO2016097231A2 (fr) * 2014-12-17 2016-06-23 Cellectis Récepteur d'antigène chimérique inhibiteur (icar ou n-car) exprimant un domaine de transduction non lymphocytaire t
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
WO2018102594A1 (fr) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Procédés de traitement de tumeurs solides avec des anticorps anti-cd200
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
EP4296280A1 (fr) * 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 et cd200 en tant que marqueurs pour le diagnostic et l'immuno-éradication des cellules souches leucémiques (csl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
ES2260852T3 (es) * 1997-11-07 2006-11-01 Trillium Therapeutics Inc. Metodos y composiciones para inmunomodulacion.
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2511513A1 (fr) 2002-12-27 2004-07-22 Schering Corporation Techniques permettant d'induire et de maintenir une tolerance immunitaire
US8075884B2 (en) * 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
JP2010534242A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用

Also Published As

Publication number Publication date
AU2008279619B2 (en) 2013-11-14
EP2178561A1 (fr) 2010-04-28
US20120321625A1 (en) 2012-12-20
US8252285B2 (en) 2012-08-28
JP2015172090A (ja) 2015-10-01
WO2009014745A1 (fr) 2009-01-29
US8637014B2 (en) 2014-01-28
CA2697159C (fr) 2017-02-14
MX2010000981A (es) 2010-05-21
KR20100041849A (ko) 2010-04-22
CA2697159A1 (fr) 2009-01-29
JP2013163695A (ja) 2013-08-22
AU2008279619A1 (en) 2009-01-29
JP5926702B2 (ja) 2016-05-25
USRE46323E1 (en) 2017-02-28
JP2010534243A (ja) 2010-11-04
US20100291085A1 (en) 2010-11-18
JP2016117762A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
BRPI0814644A2 (pt) Anticorpos para cd200 e usos destes na inibição de respostas imunes.
BRPI1010540A2 (pt) "anticorpos especéficos para dkk-1 e seus usos"
CY2018018I2 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
BRPI0812005A2 (pt) anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
CR10466A (es) Anticuerpos e inmunoconjugados y sus usos
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI0815983A2 (pt) anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
DK2176296T3 (da) Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
BRPI0907530A2 (pt) Anticorpos direcionados à angiopoietina-1 angiopoietina-2 e seus usos
BRPI0816785A2 (pt) bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
BRPI0717638A2 (pt) Anticorpors e imunoconjugados e usos para os mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0815564A2 (pt) Anticorpos que inibem a dimerização de c-met e usos dos mesmos.
BRPI0819598A2 (pt) anticorpos para o antígeno pcrv da pseudomonas aeruginosa
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
ATE496849T1 (de) Getränkeinhaltstoffkapsel
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0906498A2 (pt) Anticorpo ron e seus usos
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.